Pancreatic cancer-Associated retinoblastoma 1 dysfunction enables TGF-?beta;?to promote proliferation

Journal of Clinical Investigation

Volumn 124, Issue 1, 2014, Pages 338-352

  Jesse Gore, A ^a   Deitz, Samantha L ^a   Palam, Lakshmi Reddy ^a   Craven, Kelly E ^a   Korc, Murray ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH INHIBITION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MITOGENESIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; STROMA; STROMA CELL; TUMOR GROWTH; WNT SIGNALING PATHWAY;

EID: 84892912591     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71526     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30
2. Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: advances to date and future directions. Drugs. 2006;66(8):1059-1072
3. Kern SE. Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med Clin North Am. 2000;84(3):691-695
4. Korc M. Pancreatic cancer-Associated stroma production. Am J Surg. 2007;194(4 suppl):S84-S86
5. McCleary-Wheeler AL, et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 2013;328(2):212-221
6. Preis M, Korc M. Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther. 2010;9(10):754-763
7. Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int. 2011;2011:620601
8. McCleary-Wheeler AL, McWilliams R, Fernandez- Zapico ME. Aberrant signaling pathways in pancreatic cancer: A two compartment view. Mol Carcinog. 2012;51(1):25-39
9. Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10(10):683-695
10. Friess H, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 1993;105(6):1846-1856
11. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth factor-beta (TGF-Â) receptor inhibits TGF-Â signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res. 2001;7(9):2931-2940
12. Melisi D, et al. LY2109761, a novel transforming growth factor-beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008;7(4):829-840
13. Hezel AF, et al. TGF-Â and ávâ6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res. 2012;72(18):4840-4845
14. Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-450
15. Bardeesy N, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130-3146
16. Bardeesy N, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006;103(15):5947-5952
17. Aguirre AJ, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112-3126
18. Carrière C, et al. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology. 2011;141(3):1091-1101
19. Qiu W, et al. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget. 2011;2(11):862-873
20. Liang WS, et al. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7(10):e43192
21. Derynck R, Feng X-H. TGF-Â receptor signaling. Biochim Biophys Acta. 1997;1333(2):F105-F150
22. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220-5227
23. Boyer Arnold N, Korc M. Smad7 abrogates transforming growth factor-Â1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. J Biol Chem. 2005;280(23):21858- 21866
24. Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-1806
25. Barrientes S, Cooke C, Goodrich DW. Glutamic acid mutagenesis of retinoblastoma protein phosphorylation sites has diverse effects on function. Oncogene. 2000;19(4):562-570
26. Herrera RE, Makela TP, Weinberg RA. TGFâ-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein. Mol Biol Cell. 1996;7(9):1335-1342
27. Ko TC, Sheng HM, Reisman D, Thompson EA, Beauchamp RD. Transforming growth factor-Â 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene. 1995;10(1):177-184
28. Sempere LF, Gunn JR, Korc M. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFâ in pancreatic cancer cells. Cancer Biol Ther. 2011;12(3):198-207
29. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-Â type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004;65(3):744-752
30. Attisano L, Labbe E. TGFâ and Wnt pathway crosstalk. Cancer Metastasis Rev. 2004;23(1-2):53-61
31. Pasca di Magliano M, et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One. 2007;2(11):e1155
32. Yu M, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487(7408):510-513
33. Chen B, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5(2):100-107
34. Üren A, et al. Secreted frizzled-related protein-1 binds directly to wingless and is a biphasic modulator of Wnt signaling. J Biol Chem. 2000;275(6):4374-4382
35. Shu W, Jiang YQ, Lu MM, Morrisey EE. Wnt7b regulates mesenchymal proliferation and vascular development in the lung. Development. 2002;129(20):4831-4842
36. Arensman MD, et al. WNT7B mediates autocrine Wnt/[beta]-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma [published online ahead of print February 18, 2013]. Oncogene. doi:10.1038/onc.2013.23
37. Wagner KW, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007; 13(9):1070-1077
38. Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-307
39. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11-26
40. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674
41. Massagué J. TGFâ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616-630
42. Schutte M, et al. Abrogation of the Rb/p16 tumorsuppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57(15):3126-3130
43. Park J-K, et al. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 2011;406(4):518-523
44. Park BJ, Park JI, Byun DS, Park JH, Chi SG. Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-Activated protein kinase signaling pathway in human prostate cancer. Cancer Res. 2000;60(11):3031-3038
45. Galliher-Beckley AJ, Schiemann WP. Grb2 binding to Tyr284 in TâR-II is essential for mammary tumor growth and metastasis stimulated by TGF-Â. Carcinogenesis. 2008;29(2):244-251
46. Gatza CE, et al. Type III TGF-Â receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia. 2011;13(8):758-770
47. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323-330
48. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52-58
49. Furuuchi K, et al. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol. 2000;156(6):1997-2005
50. Satoh S, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24(3):245-250
51. Wang L, et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and â-catenin stabilization. Cancer Cell. 2009;15(3):207-219.